Sign in
Taking people in PolandPhase 1

Tests trametinib and gilteritinib in adults with relapsed or hard-to-treat acute leukemia

Tests two drugs, trametinib and gilteritinib, in adults with relapsed or hard-to-treat acute leukemia.

Key facts

Who runs it
Instytut Hematologii I Transfuzjologii
Where
Gdansk, Katowice, Poznan, Warsaw, and Wrocław, PolandSee the 6 sites
Registry title
Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
Status
Recruiting
Phase
Phase 1
People taking part
54 people, planned
Started
28 Jan 2022
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute leukemia (ALL or AML) that came back or did not respond to treatment, who have no other treatment options.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Acute lymphoblastic (ALL) or acute myeloid (AML) leukemia that has relapsed or did not respond to treatment, in people who cannot have treatment meant to remove all of the disease.
Earlier treatment
People must have no other treatment options available.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Poland

  • Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Samodzielny Publiczny Szpital Kliniczny Im.Adrzeja Mieleckiego Slaskiego Uniwersytetu MedycznegoKatowice, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych I Administracji W Poznaniu Im. Prof. Ludwika BierkowskiegoPoznan, PolandTaking people
  • Uniwersytet Medyczny w PoznaniuPoznan, PolandTaking people
  • Instytut Hematologii I TransfuzjologiiWarsaw, PolandTaking people
  • Uniwersytet Medyczny we WrocławiuWrocław, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests trametinib and gilteritinib in adults with relapsed or hard-to-treat acute leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 October 2026